MobileODT will participate in India’s ambitious nationwide project for cervical cancer early detection
22 November, 2021
The project aims to screen all women in India at ages 30-65. MobileODT has developed device which enable early detection of cervical cancer using Smartphone. Around 5,000 MobilODT's kits will be used in the project
The project will be run by Karkinos Healthcare company, specialized in technologies for early cancer detection, in collaboration with GenWorks Health, MobileODT’s exclusive distributor in India. The tests will be conducted by World Health Organization’s (WHO) recommended Human Papilloma Virus (HPV) DNA test for early detection of cervical cancer among women followed by colposcopy exam. In the current project, the colposcopy exams will be performed using MobilODT’s device. According to MobileODT’s estimation, around 5,000 EVA kits will be used in the project.
“We are extremely proud that the EVA technology has been selected to be part of this endeavor together with our partner Genworks, in this effort to eliminate cervical cancer in India. This is one of the largest national programs of its kind” says Leon Boston, MobileODT’s CEO,” our unique algorithm, allows an unprecedented screening at scale, that can be life saving for many women around the world”.
A Mobile Colposcopy Using Smartphones
MobileODT, which was established in 2012 and is now run by the CEO Leon Boston, developed an inexpensive and mobile kit called EVA System, which is based on the smartphone’s photography and processing abilities and allows it to perform the vaginal colposcopy. The kit includes a zoom lense that is attached to the smartphone camera and a powerful lighting unit that allows clear imaging of the cervix. After the test, the images can be sent to gynecologists and experts through the application for diagnosis. In addition, the product also includes a smart decoding of the test, based on algorithms developed using machine learning performed on large databases of patient’s cervical imaging.
This assessment allows nurses, midwives and therapists to simply perform the diagnostic test even in remote locations and countries in which medical infrastructure is lacking, and thus help lessen the cervical cancer mortality rates. The EVA System kit which received FDA approval in 2016, is sold today in about 30 countries and is in use in 60 clinics in the US.